Loading organizations...
Loading organizations...
On-Q-ity is a technology company.
On-Q-ity developed diagnostic products and services focused on capturing and characterizing circulating tumor cells (CTCs). Its technology provided clinical researchers and physicians with enhanced decision-making tools for various cancer types. This non-invasive platform leveraged advanced cell biology to monitor cancer progression and predict treatment response, enabling precise, patient-specific analysis.
On-Q-ity was formed in 2009 through the merger of two predecessor diagnostic companies, Cellective Dx and DNAR (DNA Repair Inc.). This consolidation integrated promising DNA repair biomarker and circulating tumor cell capture technologies. The founding insight centered on the critical need for personalized cancer diagnostics, attracting experienced executives and scientists.
The company targeted clinical researchers and oncologists to improve patient care. On-Q-ity's mission aimed to enhance oncology drug development, improve treatment outcomes, and extend cancer patient survival. Its vision sought to establish the CTC analysis platform as crucial for personalized cancer management, informing therapeutic strategies with patient insights.
On-Q-ity has raised $31.0M across 2 funding rounds.
On-Q-ity has raised $31.0M in total across 2 funding rounds.
On-Q-ity is a life sciences company specializing in cancer diagnostics, focused on circulating tumor cell (CTC) capture and characterization to personalize cancer therapy and improve patient outcomes.[1][3] It develops technologies in in vitro diagnostics, molecular diagnostics, genetic testing, and pharmacogenetics for the biotechnology sector.[5] Formed through a merger, the company raised $21M in Series A funding to advance its CTC-based products and services targeting oncologists and cancer patients, addressing the challenge of tailoring treatments via tumor profiling.[1][2]
On-Q-ity emerged in 2009 from the merger of two venture-backed diagnostic firms: Cellective Dx and DNAR (DNA Repair Inc.), combining expertise in cancer diagnostics.[2] This union created a platform for next-generation tools in CTC analysis, building on predecessors' work in tumor cell detection and DNA repair assays.[2][3] Early momentum included securing $21M in Series A funding to develop technologies for personalizing cancer therapy, marking a pivotal push toward commercialization despite later challenges.[1]
On-Q-ity rides the precision oncology trend, where liquid biopsies and CTC analysis enable real-time tumor monitoring amid rising demand for targeted therapies.[1][3] Timing aligned with early 2010s advances in genomics and immunotherapy, fueled by market forces like increasing cancer incidence and shift from one-size-fits-all chemo to biomarker-driven care.[5] Though its influence waned post-2013 (noted as defunct in some records), it contributed to the startup ecosystem by validating CTC tech, paving the way for successors in the $10B+ diagnostics market.[2]
Search results indicate On-Q-ity ceased operations around 2013, limiting active trajectory, with no evidence of revival by 2025.[2] Emerging trends like AI-enhanced CTC platforms and multi-omics integration could inspire similar ventures, but On-Q-ity's legacy endures in advancing personalized diagnostics. Its story underscores biotech risks—strong funding and tech don't guarantee longevity—yet highlights CTC's enduring role in transforming cancer care, echoing its original mission to redefine patient outcomes.[1][3]
On-Q-ity has raised $31.0M in total across 2 funding rounds.
On-Q-ity's investors include Kleiner Perkins, Atlas Ventures, Sue Siegel, Physic Ventures, Bruce Booth, Steve Kraus, Northgate Capital, Dion Madsen.
On-Q-ity has raised $31.0M across 2 funding rounds. Most recently, it raised $5.0M Series B in February 2012.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Feb 1, 2012 | $5.0M Series B | Kleiner Perkins, Atlas Ventures, Sue Siegel, Physic Ventures | |
| Dec 1, 2009 | $26.0M Series A | Sue Siegel | Kleiner Perkins, Bruce Booth, Steve Kraus, Northgate Capital, Dion Madsen |